血友病临床试验中种族与民族报告及代表性
该横断面研究查询了2007至2022年ClinicalTrials.gov上涉及血友病患者的129项干预性临床试验,发现52.0%报告了种族与民族数据,且报告率从13.9%升至100%(P=0.001);黑人与西班牙裔参与者代表性不足,观察与预期比值约低75%。
要点
- 2007-2022年129项血友病试验中仅52.0%报告种族与民族数据,报告率随时间显著提高(P=0.001)。
- 报告数据的66项试验中,白人占65.8%、亚裔22.8%、西班牙裔5.1%、黑人3.9%。
- 黑人与西班牙裔的观察与预期比值较美国血友病治疗中心及美国人口普查低约75%。
核心结论
- 血友病临床试验的种族与民族报告已大幅改善,但黑人与西班牙裔血友病患者仍尤其代表性不足。
- 为解决这些差异,临床试验各相关方需实施策略以确保公平参与。
研究设计与样本
- 横断面研究,于2023年4月查询ClinicalTrials.gov数据库,纳入2007至2022年间涉及血友病患者的干预性临床试验。
- 共纳入129项试验,94.6%由企业申办,平均62名参与者,平均年龄26.8岁。
主要发现
- 52.0%(n=66)的试验报告了种族与民族数据,报告率从2007-2012年的13.9%升至2013-2016年的22.5%,再升至2017-2022年的100%(P=0.001)。
- 在66项报告数据的试验中,白人、亚裔、西班牙裔和黑人参与者分别占65.8%、22.8%、5.1%和3.9%。
- 白人参与者的观察与预期比值较美国血友病治疗中心及美国、英国、加拿大人口普查数据低10%至20%。
- 黑人或西班牙裔参与者的观察与预期比值较美国血友病治疗中心和美国人口普查数据低约75%。
- 亚裔参与者的观察与预期比值较加拿大、美国、英国人口普查数据高1.6至3倍。
关键数值与推荐
- 原文未报告
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Racial and ethnic representativeness in clinical trials is crucial to mitigate disparities in outcomes; however, diversity among hemophilia trials is unknown. The aim of this study is to examine the reporting and representation of race and ethnicity in trials of people with hemophilia (PwH). In this cross-sectional study, the ClinicalTrials.gov database was queried in April 2023 for interventional clinical trials involving PwH between 2007 and 2022. The distribution of participants (observed) was compared with expected proportions based on US Hemophilia Treatment Center (HTC) and country-specific census data with observed-to-expected ratios (OERs). Of 129 trials included, 94.6% were industry sponsored, with a mean of 62 participants and mean age of 26.8 years. Overall, 52.0% (n = 66) of trials reported data on race and ethnicity, increasing from 13.9% in 2007-2012 to 22.5% in 2013-2016 to 100% in 2017-2022 (P = .001). Among these 66 trials, 65.8%, 22.8%, 5.1%, 3.9% of participants were White, Asian, Hispanic, and Black, respectively. OERs were 10% to 20% lower for White participants vs US HTC, and US, UK, and Canadian census populations and ∼75% lower for Black or Hispanic participants when compared with US HTC and US census population. OERs for Asian participants were 1.6 to 3 times higher than Canada, US, and UK census populations. The reporting of race and ethnicity in hemophilia trials has drastically improved; however, Black and Hispanic PwH remain especially underrepresented. To address these disparities, stakeholders across the clinical trial enterprise need to implement strategies to ensure equitable participation.
引用
- Fedewa SA, Valentino LA, Koo A, et al. Race and ethnicity reporting and representation in hemophilia clinical trials. Blood Adv. 2024. PMID: 38547444. doi:10.1182/bloodadvances.2024012862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。